A Study of Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of VE-01902 in Healthy Volunteers
A multi-center, double-blinded, randomized, placebo-controlled, single ascending dose study with food effect crossover and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and hemostatic profile of VE-01902
VCR1
134 participants
Jan 15, 2019
Interventional
Conditions
Summary
A multi-center, double-blinded, randomized, placebo-controlled, single ascending dose study and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and hemostatic profile of VE-01902. The single ascending dose phase will encompass a single bridging cohort across tablet strengths, and a food effect cohort.
Eligibility
Inclusion Criteria17
- Male or female aged 18 to 55 years, inclusive;
- Body mass index (BMI) between 19 and 33 kg/m2 inclusive, with a minimum weight of 50 kg;
- Healthy as determined by pre-study medical history, physical examination, vital signs,
- complete neurological examination and 12-lead electrocardiogram (ECG) confirming normal sinus rhythm;
- Negative tests for Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV)
- and human immunodeficiency virus (HIV)-1and HIV-2 antibody at screening;
- Routine laboratory screening tests as specified below should be within normal limits or any abnormalities should be not clinically significant, as determined by the investigator at screening and day -1; however, results of the coagulation panel, platelet count and hemoglobin should be within normal limits, and liver function tests (specifically, total bilirubin, ALT and AST) should not exceed 1.5x the upper limit of normal;
- Negative screen for alcohol and drugs of abuse at screening and admission;
- Non-smokers or casual smoker who uses no more than 10 cigarettes (or equivalent quantity of any other nicotine containing products e.g. cigars, chewing tobacco, snuff, vaping, e-cigarettes, and etc.) per week. Subject must abstain from smoking 5 days prior to admission and throughout the entire study period, and test negative on Day -1 for urine cotinine test. ;
- Female participants:
- Must be of non-child-bearing potential by surgical sterilization or postmenopausal (no menses for the previous 12 months without alternative medical cause and confirmed by FSH testing),
- OR
- Must not be pregnant, breast feeding, or planning to become pregnant AND must be practicing both a highly effective method of birth control for at least 30 days after the last dose of study drug and a barrier method (such as condom use). Highly-effective methods of birth control include: hormonal contraception (e.g. birth control pill, injection, implant, transdermal patch or vaginal ring), an intrauterine device, tubal ligation or a sole partner with a vasectomy. Progestin-based contraception that suppresses ovulation (e.g. Depo-Provera) is allowed. Estrogen-containing contraceptives that provide suppression of ovulation may be allowed. However, high-dose estrogen (greater than 35 microgram ethinyloestradiol)-containing contraceptives are not allowed in this study. Gonadotropin-releasing hormone agonist contraceptives are not allowed in this study. Abstinence from penile-vaginal intercourse for the above duration is acceptable, if it is consistent with the usual and preferred lifestyle of the participant;
- Negative serum pregnancy test at screening and negative urine pregnancy test on admission of each treatment period (women of childbearing potential only);
- Male participants:
- Must be practicing a highly effective method of birth control with female partners of
- childbearing potential from screening throughout the study and for at least 90 days after the last investigational drug administration. Highly effective birth control methods are as described above and include vasectomy, or condom use in combination with partner’s use of highly effective contraception
Exclusion Criteria20
- Aspirin or Non-steroidal anti-inflammatory drug (with the exception of acetaminophen) use in the preceding 2 weeks.
- Have used any anticoagulants independent of participating in a clinical trial, or if anticoagulant use was due to participation in a clinical trial then washout period should be maximum of the longer period of either 5x PK t1/2 or PD t1/2
- Have any significant hematologic past medical history of hypercoagulable or bleeding disorders, unexplained bleeding, bruising, hemorrhage, blood clots, or thromboembolism as determined by the PI;
- Have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
- Have a clinically relevant surgical history (surgery within the last 2 months, planned surgery within the following month);
- Have a history of hyperemesis, Crohn’s, Inflammatory Bowel Disease, Irritable Bowel Syndrome, hematuria, melena, hematochezia;
- Have a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis;
- Have a history of alcoholism or drug abuse;
- Consume more than 14 units of alcohol a week (1 unit of EtOH = 1 glass (25 cl) of beer with 3% of alcohol = 7.5 g, or 1 glass (25 cl) of beer with 6% of alcohol = 15 g, or 1 glass (12.5 cl) of wine with 10% of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42% of alcohol = 17 g] on history, or exhibit detectable alcohol levels by breathalyzer;
- Have a significant infection or known inflammatory process on screening or admission (ie. infection, autoimmune disease, immunosuppression regimen);
- Have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the time of screening or admission;
- Have used any prescription medicines, over the counter medicines, or herbal supplements, within two weeks of admission, with the exception of acetaminophen or approved method of hormonal contraception;
- Have used any investigational drug or participated in any clinical trial within 90 days prior (or if longer, 5 times the half life of the investigational product) to screening;
- Have participated in more than 1 clinical trial within the 3 months prior to screening;
- Have donated or received any blood or blood products within the 3 months prior to screening;
- Have medical dietary restrictions that cannot be accommodated by the clinical unit;
- Are an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted.
- Cannot communicate reliably with the investigator;
- Are unlikely to co-operate with the requirements, including duration of admission to the study and expected follow up visit;
- Are unwilling or unable to give written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Healthy volunteer study with single dose and multiple ascending doses: For the SAD, VE-01902 will be administered to fasted patients as an enterically coated oral tablet or as an oral suspension starting at 45mg/kg/day for 1 day of dosing. There will be 6 cohorts, with an option to add a 7th if a certain PD threshold has not been met, and there were no serious safety signals. The second cohort will be used to investigate the differences between the different tablet strengths. Dosing levels will be adaptively decided after each dosing of a cohort via reviewing the PD and safety data by the safety review committee (SRC). There will be a maximum increase of 3x. Once a cohort hits a certain biologically relevant dose, a portion of subjects from a single cohort will be brought back for the same dose of drug, after a 9 day washout period. This dose will be administered after a high-fat breakfast to assess the effect of food on the drug. The ensuing SAD cohorts will be dosed in a fasted or fed state, depending on these results. The maximum dose will be decided by reviewing PD and safety data, passed down from the SRC. For the MAD, VE-01902 will be administered, to either fasted or fed patients depending on the food effect cohort, as an enterically coated oral tablet or as an oral suspension starting at a dose level decided from the SAD's available data, for 7 consecutive days of once-a-day dosing in the first MAD cohort. After the first cohort, the dose will be administered for 5 consecutive days of once-a-day dosing. There will be 4 cohorts, with an option to add a 5th if a certain PD threshold has not been met, and there were no serious safety signals. The maximum dose will be decided by reviewing PD and safety data, passed down from the safety review committee. Adherence will be monitored through visual confirmation of dosing.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001509257